Abbott Extends Use of Compugen s Genecarta Database | GenomeWeb

NEW YORK, Feb. 18 (GenomeWeb News) - Abbott Laboratories will continue to use Compugen's Genecarta technology for analyzing novel drug targets, Compugen said today.

 

Under the extended agreement, which started in early 2003, Abbott will receive several updates of Compugen's Genecarta database.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.